Evidence poor for link between biomarkers and risk of CV events for patients with kidney disease

Mar 15, 2011

Even though clinical practice guidelines for patients with chronic kidney disease recommend specific treatment target levels for serum phosphorus, parathyroid hormone, and calcium to reduce the risk of cardiovascular events, an analysis of data from previous studies did not find a strong association between these biomarkers and the risk of death and cardiovascular events, except for higher serum phosphorus levels, according to an article in the March 16 issue of JAMA.

"Nephrology guidelines recommend targets and treatment strategies to correct of phosphorus, calcium, and hormone because observational data suggest there is an association between these potential risk biomarkers and vascular disease and death. However, to date, randomized controlled trials have not shown that treating mineral levels with existing treatment options reduces cardiovascular events or mortality," according to background information in the article. The authors add that existing guidelines (based primarily on observational studies) may be inappropriately promoting treatment for abnormal mineral metabolism in individuals with .

Suetonia C. Palmer, M.B., Ch.B., Ph.D., of the University of Otago, Christchurch, New Zealand, and colleagues conducted a review and meta-analysis to evaluate the quality of evidence for the association between levels of serum phosphorus, , and calcium and risks of death, cardiovascular death, and nonfatal in individuals with chronic kidney disease. Through a search of databases, the researchers identified 47 studies (n = 327,644 patients) that met the inclusion criteria.

The analysis indicated that for every 1-mg/dL increase in serum phosphorus, the risk of death increased 18 percent. "There was no significant association between all-cause mortality and serum level of parathyroid hormone or serum level of calcium. Data for the association between serum level of phosphorus, parathyroid hormone, and calcium and cardiovascular death were each available in only 1 adequately adjusted cohort study," the authors write.

"… based on the available cohort data and the absence of randomized controlled trials, the evidentiary basis for current clinical guideline-recommended targets of serum phosphorus, parathyroid hormone, and calcium in chronic kidney disease is poor. Broad adoption of health care practices that have insufficient evidence for safety or efficacy (in this case targeting serum mineral levels in individuals with chronic kidney disease) may lead to considerable unintended harm," the authors write.

"Large placebo-controlled randomized trials of vitamin D compounds, phosphorus binders, and calcimimetic agents are now needed to evaluate whether treating mineral disorders improves health outcomes for individuals with chronic kidney disease."

Explore further: New hope for rare disease drug development

More information: JAMA. 2011;305[11]1119-1127.

add to favorites email to friend print save as pdf

Related Stories

Vitamin D linked to reduced mortality rate in CKD

May 07, 2008

For patients with moderate to severe chronic kidney disease (CKD), treatment with activated vitamin D may reduce the risk of death by approximately one-fourth, suggests a study in the August Journal of the American Society of ...

Kidney disease patients reap rewards of prevention

May 07, 2009

Making sure you see your doctor and have tests run on a regular basis can prevent serious complications of chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American So ...

Recommended for you

New hope for rare disease drug development

1 hour ago

Using combinations of well-known approved drugs has for the first time been shown to be potentially safe in treating a rare disease, according to the results of a clinical trial published in the open access Orphanet Journal of ...

Three weeks since last Ebola case in Mali: WHO

4 hours ago

Mali has not had a case of Ebola for three weeks, the World Health Organization said Wednesday, completing one of the two incubation periods the country needs to be declared free of the virus.

Migraine may double risk for facial paralysis

5 hours ago

Migraine headache may double the risk of a nervous system condition that causes facial paralysis, called Bell's palsy, according to a new study published in the December 17, 2014, online issue of Neurology, the medical journa ...

Anti-diabetic drug springs new hope for tuberculosis patients

12 hours ago

A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that Metformin (MET), a drug for treating diabetes, can also be used to boost the efficacy of TB medication without inducing ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.